Leaving the study early · patients with alcohol dependence
Anticonvulsants showed no clear difference in dropouts compared with placebo (moderate certainty).
1 finding from 1 review
Continuous abstinence rate at · patients with alcohol dependence
Anticonvulsants showed no clear difference in continuous abstinence compared with placebo (moderate certainty).
1 finding from 1 review
Drinks per drinking day · patients with alcohol dependence
1 finding from 1 review
Heavy drinking · patients with alcohol dependence
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with alcohol dependence
Anticonvulsants showed no clear difference in adverse events—withdrawn for medical reasons compared with placebo (moderate certainty).
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 2: anticonvulsants/GABAs probably leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 2: anticonvulsants/GABAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Abstinence · cannabis dependence
It is very uncertain whether anticonvulsants and mood stabilisers changes participants abstinent at end of treatment compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
It is very uncertain whether anticonvulsants and mood stabilisers changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Completion of scheduled treatment · cannabis dependence
Anticonvulsants and mood stabilisers may leads to lower completion of scheduled treatment compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: drowsiness (gabapentin alone) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day) changes adverse effects: drowsiness (gabapentin alone) compared with placebo (very low certainty).
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin + alpha lipoic acid) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: mild headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin + alpha lipoic acid) changes adverse effects: mild headache compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review